Introduction
============

COPD is characterized by the progressive development of airflow limitation that is not fully reversible.[@b1-copd-11-1367] COPD has been estimated to become the third leading cause of death in the world by 2020.[@b2-copd-11-1367] According to statistics, COPD is ranked as the third and fourth leading cause of death in rural and urban areas of the People's Republic of China, respectively.[@b3-copd-11-1367] Cigarette smoking is considered to be a major environmental factor contributing to the development of COPD. However, only 25%--40% of cigarette smokers develop COPD,[@b4-copd-11-1367] indicating that other components may be involved in COPD development.[@b5-copd-11-1367]--[@b7-copd-11-1367]

Accumulated evidence indicates that genetic factors influence COPD susceptibility. A number of studies have demonstrated that TNF-α is relevant to the pathogenesis of COPD, including involvement in neutrophil release from the bone marrow and neutrophil activation.[@b8-copd-11-1367] Increased levels of TNF-α have been found in the sputum,[@b9-copd-11-1367] bronchoalveolar lavage fluid, bronchial biopsies, and circulation[@b10-copd-11-1367] of COPD patients. Genetic polymorphism analyses have identified several single-nucleotide polymorphisms in the TNF-α gene associated with COPD risk, including −238 G/A, −308 G/A, −376 G/A, −863 C/A, −857 T/C, −1031 T/C, and +489 G/A.[@b11-copd-11-1367]--[@b14-copd-11-1367] Among these, the −308 G/A polymorphism is the best studied; however, a consistent association has not yet been found.[@b15-copd-11-1367] Studies in Asians[@b16-copd-11-1367],[@b17-copd-11-1367] and non-Asians[@b18-copd-11-1367] have demonstrated that the TNF-α −308 G/A polymorphism is associated with an increased risk of COPD. However, other studies in both Asians[@b19-copd-11-1367],[@b20-copd-11-1367] and non-Asians[@b21-copd-11-1367]--[@b25-copd-11-1367] have showed opposite results.

A limited number of meta-analyses have been performed to further clarify the association between the TNF-α −308 polymorphisms and COPD risk;[@b26-copd-11-1367]--[@b29-copd-11-1367] however, a firm conclusion has not been achieved because of several limitations in the previous meta-analyses including 1) failure to check the Hardy--Weinberg equilibrium (HWE), 2) lack of quality assessment, 3) inappropriate genetic model, and 4) a limited number of included studies. All these factors have led to considerable argument regarding the studies' paradoxical conclusions. Additionally, only studies published up to 2010 were included in the most recent meta-analysis.[@b29-copd-11-1367] In the present study, we conducted a meta-analysis update with studies published up to July 2015. Additionally, we followed a stricter procedure: 1) only studies in accordance with HWE were included, 2) all included studies had a quality score no less than 5 because studies with quality scores ≤4 are considered as low-quality studies,[@b30-copd-11-1367] and 3) the most appropriate genetic model was employed. Thus, our report presented more detailed information which will not only help obtain a clearer understanding of the association between TNF-α −308 polymorphisms and COPD but also help pave the way for individualized treatment of COPD patients.

Materials and methods
=====================

The current meta-analysis was conducted according to the guidelines presented in the review by Sagoo et al.[@b31-copd-11-1367]

Search strategy for publication
-------------------------------

A comprehensive search was conducted using the terms "TNF", "tumor necrosis factor", "polymorphism", and "COPD" in several electronic databases (PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Database of Chinese Scientific and Technical Periodicals, China Biology Medicine disc database, and WANFANG databases) to identify studies that examined the association of TNF-α −308 (rs1800629) G/A polymorphisms with COPD published up to July 2015. Additional studies were identified by manually reviewing the bibliographies of relevant articles as well as relevant review articles. The search was performed without restriction regarding race, ethnicity, or geographic area. Only published studies with full text in English or Chinese were included. Concerning duplicate populations included in several publications, only the most recent or complete study was included in this meta-analysis.

Eligibility criteria
--------------------

Eligible studies were required to meet the following inclusion criteria: 1) evaluation of the TNF-α −308 polymorphism and COPD risk, 2) employment of a case--control design, 3) inclusion of adult subjects within the case group or control group, 4) disclosure of the number of individual genotypes with COPD in cases and controls, and 5) congruency of the distribution of genotypes among controls with HWE. Studies were excluded if 1) they contained overlapping data with another study, 2) the number of wild-type genotypes or alleles was not stated, and 3) they reviewed only editorials, reviews, and abstracts. All articles were reviewed to determine eligibility by two independent investigators. A consensus with a third reviewer was needed if there was any disagreement between the two investigators.

Data extraction
---------------

Data were checked and extracted from each study by two independent investigators. Data inconsistencies or discrepancies were resolved by consensus of all investigators before being standardized into a unified dataset. The following information was extracted from each study: first author's name, publication year, country/territory, numbers of cases and controls, ethnicity of the study population, source of control subjects, smoking status in cases and controls, and genotype and allele distribution.

Quality assessment
------------------

The Newcastle--Ottawa quality assessment scale[@b32-copd-11-1367] was applied to assess the quality of each study by two investigators. The quality was evaluated with three major components: 1) selection of cases and controls, 2) comparability of cases and controls, and 3) ascertainment of exposure. Any disagreement was resolved by a third investigator. Only studies with a quality score ≥5 were included in the current study.

Statistical analysis
--------------------

Statistical analysis was performed according to standard procedures.[@b30-copd-11-1367] Pooled odds ratios (ORs) were calculated with the Mantel--Haenszel (M--H) mean of the logarithm with a 95% confidence interval (CI). First, an allele comparison was conducted to determine the allele risk. Second, OR1, OR2, and OR3 were explored for the genotypes (GG vs AA \[OR1\], GG vs GA \[OR2\], and GA vs AA \[OR3\]) to identify the most appropriate genetic model. When OR1 = OR3 ≠1 and OR2 =1, a recessive model was suggested. When OR1 = OR2 ≠1 and OR3 =1, then a dominant model was suggested. When OR1 \> OR2 \>1 and OR1 \> OR3 \>1 (or OR1 \< OR2 \<1 and OR1 \< OR3 \<1), then a codominant model was suggested.[@b33-copd-11-1367] Lastly, the most appropriate genetic model was used to pool the results.

Heterogeneity was assessed by using the chi-square-based Cochran *Q*-test, which was considered significant if *P*\<0.10, and the *I*^2^ statistic. If *I*^2^\>50%, the random-effect model was adopted as the pooling method; otherwise, the fixed-effect model was used. To explore the source of the heterogeneity, subgroup analyses were performed with respect to ethnicity and smoking status.

A sensitivity analysis was conducted to assess the stability of the results. One study at a time was excluded to evaluate how robust the pooled estimator was. Publication bias was estimated by using Egger's test.

All statistical analyses were performed with STATA version 11.0. A *P*-value \<0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

The flow diagram in [Figure 1](#f1-copd-11-1367){ref-type="fig"} summarizes the selection process carried out for this meta-analysis. A total of 38 eligible articles were included in the current meta-analysis, comprising 3,951 COPD cases and 5,110 controls.[@b11-copd-11-1367]--[@b13-copd-11-1367],[@b16-copd-11-1367],[@b18-copd-11-1367],[@b19-copd-11-1367],[@b22-copd-11-1367],[@b24-copd-11-1367],[@b34-copd-11-1367]--[@b63-copd-11-1367] Twenty articles were published in English and 18 in Chinese. There were 16 studies performed in non-Asians which comprised 1,884 COPD cases and 2,943 controls and 22 studies in Asians which comprised 2,067 COPD cases and 2,167 controls. Fifteen studies contained sufficient information for subgroup analysis by smoking status. All of the cases were confirmed by the diagnostic criteria of COPD.[@b64-copd-11-1367]--[@b68-copd-11-1367] The genotype distributions of the TNF-α −308 polymorphism were in accordance with HWE in the controls of all the studies. Based on the quality assessment scale for case--control studies, two studies scored 5 points, 22 studies scored 6 points, eleven studies scored 7 points, and the other three scored 8 points. The characteristics of these studies are shown in [Table 1](#t1-copd-11-1367){ref-type="table"}. The detailed genotype, allele information, and HWE results are listed in [Table 2](#t2-copd-11-1367){ref-type="table"}.

Meta-analysis results
---------------------

A summary of the meta-analysis results concerning association between TNF-α −308 polymorphism and COPD risk is provided in [Table 3](#t3-copd-11-1367){ref-type="table"}. The A allele was associated with an increased COPD risk in the overall population (OR =1.56, 95% CI 1.29--1.89, *P*=0.000 for heterogeneity, *I*^2^=70.8%) ([Figure 2](#f2-copd-11-1367){ref-type="fig"}). The estimated OR1, OR2, and OR3 were 1.776 (*P*=0.000), 1.513 (*P*=0.211), and 1.216 (*P*=0.000), respectively, suggesting a codominant model as the most appropriate genetic model. Then, the pooled ORs were calculated under the codominant genetic model. OR was 1.78 for GG vs AA and 1.51 for GG vs GA ([Figures 3](#f3-copd-11-1367){ref-type="fig"} and [4](#f4-copd-11-1367){ref-type="fig"}), demonstrating a significant association between TNF-α −308 polymorphism and COPD in the overall population. Individuals with AA genotype were more susceptible to develop COPD than those with GA genotype. To identify the origin of heterogeneity, a subgroup analysis stratified by ethnicity was conducted. As shown in [Figures 2](#f2-copd-11-1367){ref-type="fig"}[](#f3-copd-11-1367){ref-type="fig"}--[4](#f4-copd-11-1367){ref-type="fig"}, a stronger correlation of the polymorphism with COPD risk was found in Asians under the genetic model (OR =3.25 for GG vs AA and OR =2.22 for GG vs GA), and similar results were observed in the allelic model. Interestingly, the AA genotype carriers had a higher risk of developing COPD than GA carriers in Asian patients. Conversely, no association was found in non-Asians in the genetic model (OR =1.05 for GG vs AA and OR =1.00 for GG vs GA). Notably, heterogeneity was significantly decreased when stratified analysis was performed by ethnicity status in both models, indicating the ethnicity contributed partly to heterogeneity, and similar results were found in the allelic model.

Specific environmental factors, such as smoking, may contribute to the distribution of genetic polymorphisms.[@b69-copd-11-1367] Moreover, there was a difference in the TNF-α −308 polymorphism between smoking and nonsmoking COPD patients.[@b45-copd-11-1367] To minimize the effect of cigarette smoking on the association between the TNF-α −308 G/A polymorphism and COPD risk, a second meta-analysis was conducted with studies in which the COPD cases and the controls were current/former smokers. Interestingly, no significant association was found between the TNF-α −308 polymorphism and COPD risk either in Asian smokers or in non-Asian smokers. The statistics in non-Asians included OR =1.32 for GG vs AA and OR =1.07 for GG vs GA. The statistics in Asians included OR =1.66 for GG vs AA and OR =1.24 for GG vs GA ([Figures 5](#f5-copd-11-1367){ref-type="fig"} and [6](#f6-copd-11-1367){ref-type="fig"}). Our study indicated that the A allele was not a risk factor for the development of COPD in smoking populations.

Sensitivity analysis
--------------------

Sensitivity analysis was performed by sequentially excluding each study to assess the stability of the results in this meta-analysis. The corresponding pooled ORs were not materially altered in the overall meta-analysis ([Figure 7](#f7-copd-11-1367){ref-type="fig"}). In the meta-analysis with restriction to smokers, two studies[@b18-copd-11-1367],[@b47-copd-11-1367] were found to be the source of heterogeneity in Asian smokers ([Figure 8](#f8-copd-11-1367){ref-type="fig"}). After excluding these two studies from the analysis, the pooled OR did not vary significantly, indicating that the results were relatively reliable (data not shown).

Publication bias
----------------

As shown in [Figure 9](#f9-copd-11-1367){ref-type="fig"}, Egger's test was performed to assess the publication bias of the literature. No publication bias was detected (*P*=0.726).

Discussion
==========

In the present meta-analysis update, we conducted a comprehensive database search for potential articles published up to July 2015 to evaluate the association between TNF-α −308 polymorphism and COPD risk, and several of the articles were not included in the previous meta-analysis. To our knowledge, this is the first report to analyze the association between TNF-α −308 polymorphism and COPD risk under the codominant genetic model. Thus, more detailed information can be achieved under this genetic model. Finally, a total of 38 studies with 3,951 patients and 5,110 controls were included in the meta-analysis. The results showed a significant association between the TNF-α −308 polymorphism and COPD susceptibility in the overall population. Individuals with the A allele (GA or AA) were more susceptible to developing COPD than those with the GG genotype. Additionally, we further clarified that individuals with the AA genotype had a higher risk of developing COPD than those with the GA genotype (77.6% vs 51.3%). The previous meta-analysis investigating the current question employed a dominant genetic model, and did not provide detailed information about the AA and GA genotypes separately. Here, for the first time, our report indicated that carriers of the AA genotype of TNF-α −308 were the most vulnerable to COPD development.

To identify the origin of heterogeneity, a subgroup analysis stratified by ethnicity was conducted. In our study, significant associations were shown in Asians but not in non-Asians, which is consistent with the previous meta-analysis.[@b28-copd-11-1367],[@b29-copd-11-1367] Our data reconfirmed that the TNF-α −308 G/A polymorphism was associated with COPD risk even under a stricter study design and procedure. Furthermore, our study further identified a stronger correlation between the TNF-α −308 G/A polymorphism and COPD risk in Asians with the AA genotype compared with those with the GA genotype. Notably, heterogeneity was significantly decreased when the analysis stratified by ethnicity was performed. We speculated that it may be because that the A allele is more important for COPD susceptibility in Asians than in non-Asians.

To minimize the effect of smoking status on the association, a second meta-analysis restricted to smokers was conducted. Interestingly, no correlation was found between the TNF-α −308 G/A polymorphism and the risk of COPD in either Asian smokers or non-Asian smokers. This result was contrary to the previous meta-analysis which showed an obvious correlation between the TNF-α --308 G/A polymorphism and the risk of COPD in smokers. Although moderate heterogeneity was observed in Asian smokers in the allelic model, which may distort the result, the pooled OR did not vary significantly after the removal of two studies that were considered the origin of the heterogeneity. This indicated that the results of this meta-analysis in the smokers were reliable. The opposite results may be attributed to the following: 1) the codominant model was adopted in the current study, which was different from the previous study (dominant model); and 2) due to stricter inclusion criteria, several studies were excluded from the current meta-analysis. Based on the results of our study, it seems that other factors may contribute to COPD development in smokers, and we speculated that the A allele may be a risk factor in nonsmokers; however, a firm conclusion should not be drawn until a larger number of studies with a sufficient number of nonsmokers can be included in the meta-analysis.

There are several limitations of the present meta-analysis that should be considered when explaining the results: 1) Even though we followed a strict procedure for data collection and data analysis to minimize the heterogeneity, several pooled ORs were obtained from heterogeneous studies. 2) There were not enough nonsmokers in the case and control groups to conduct a subgroup analysis to ascertain whether the A allele of TNF-α --308 was associated with the risk of COPD development in the nonsmoking population. 3) The numbers of studies were limited for this meta-analysis; some studies were excluded from the study. This selection bias may have an effect on the genotyping publication bias. What's more, more studies are needed to further improve the power of the study. 4) The genotyping methods in the studies included are different, which may cause some bias on the result.

In conclusion, this meta-analysis update suggested that the A allele of TNF-α −308 is a risk factor for developing COPD. Additionally, individuals with the AA genotype appeared to be more susceptible to developing COPD than those with the GA genotype. Additionally, the subgroup analysis in Asians (but not in non-Asians) supported the results. The data presented in the current report may provide insight for COPD treatment based on patients' genotype. In future, larger and more strictly controlled studies are needed to evaluate the relationship between gene polymorphisms and COPD. What's more, relationship between gene polymorphisms and COPD in nonsmoking populations should be explored to further elucidate if gene polymorphism is an independent risk factor associated with the development of COPD, which will favor the development of effective prevention and treatment methods for COPD in nonsmokers.
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![Forest plot for the association between TNF-α --308 polymorphism and COPD in all subjects using allelic model (G vs A).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](copd-11-1367Fig2){#f2-copd-11-1367}

![Forest plot for the association between TNF-α −308 polymorphism and COPD in all subjects using codominant genetic model (G/G vs A/A genotype).\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](copd-11-1367Fig3){#f3-copd-11-1367}

![Forest plot for the association between TNF-α −308 polymorphism and COPD in all subjects using codominant genetic model (G/G vs G/A genotype).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](copd-11-1367Fig4){#f4-copd-11-1367}

![Forest plot for the association between TNF-α −308 polymorphism and COPD in smoking subjects using codominant genetic model (G/G vs A/A genotype).\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](copd-11-1367Fig5){#f5-copd-11-1367}

![Forest plot for the association between TNF-α −308 polymorphism and COPD in smoking subjects using codominant genetic model (G/G vs G/A genotype).\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](copd-11-1367Fig6){#f6-copd-11-1367}

![Sensitivity analysis for TNF-α −308 polymorphism with COPD in all subjects.\
**Abbreviation:** CI, confidence interval.](copd-11-1367Fig7){#f7-copd-11-1367}

![Sensitivity analysis for TNF-α −308 polymorphism with COPD in smoking subjects.\
**Abbreviation:** CI, confidence interval.](copd-11-1367Fig8){#f8-copd-11-1367}
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###### 

Characteristics of the included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                    Year   Country/territory            Ethnicity    Source of control                                          Genotyping method   Quality score
  ---------------------------------------- ------ ---------------------------- ------------ ---------------------------------------------------------- ------------------- ---------------
  Huang et al[@b16-copd-11-1367]           1997   Taiwan                       Asian        Healthy controls                                           PCR-RFLP            6

  Higham et al[@b22-copd-11-1367]          2000   UK                           Non-Asians   Population controls\                                       PCR-RFLP            8
                                                                                            Smoking controls                                                               

  Ishii et al[@b34-copd-11-1367]           2000   Japan                        Asian        Smoking controls                                           PCR-RFLP            7

  Keatings et al[@b35-copd-11-1367]        2000   Ireland                      Non-Asians   Smoking controls                                           PCR-RFLP            6

  Shi et al[@b36-copd-11-1367]             2000   People's Republic of China   Asian        Healthy controls\                                          PCR-RFLP            6
                                                                                            Smoking controls                                                               

  Kucukaycan et al[@b37-copd-11-1367]      2002   the Netherlands              Non-Asians   Population controls                                        PCR-DBA             6

  Ferrarotti et al[@b38-copd-11-1367]      2003   Italy                        Non-Asians   Smoking controls                                           PCR-RFLP            6

  He et al[@b39-copd-11-1367]              2003   People's Republic of China   Asian        Population controls                                        PCR-RFLP            7

  Ma et al[@b40-copd-11-1367]              2004   People's Republic of China   Asian        Patient controls                                           PCR-SSP             6

  Broekhuizen et al[@b41-copd-11-1367]     2005   the Netherlands              Non-Asians   Population controls                                        PCR-ARMS            6

  Chierakul et al[@b19-copd-11-1367]       2005   Thailand                     Asian        Population controls\                                       PCR-SSP             6
                                                                                            Smoking controls                                                               

  Hegab et al[@b42-copd-11-1367]           2005   Egypt                        Non-Asians   Population controls with matched age and smoking history   PCR-RFLP            6

  Ma et al[@b43-copd-11-1367]              2005   People's Republic of China   Asian        Population controls                                        PCR-RFLP            6

  Jiang et al[@b44-copd-11-1367]           2005   People's Republic of China   Asian        Patient controls                                           PCR-RFLP            8

  Seifart et al[@b24-copd-11-1367]         2005   Germany                      Non-Asians   Population controls\                                       PCR-RFLP            6
                                                                                            Smoking controls                                                               

  Brogger et al[@b11-copd-11-1367]         2006   Norway                       Non-Asians   Population controls                                        Real-time PCR       7

  Li et al[@b45-copd-11-1367]              2006   People's Republic of China   Asian        Population controls                                        PCR-RFLP            7

  Jiang and Li[@b46-copd-11-1367]          2006   People's Republic of China   Asian        Hospital outpatients/check-ups                             PCR-RFLP            5

  Papatheodorou et al[@b12-copd-11-1367]   2007   Greece                       Non-Asians   Population controls\                                       PCR-RFLP            6
                                                                                            Smoking controls                                                               

  Shi et al[@b47-copd-11-1367]             2007   People's Republic of China   Asian        Smoking controls                                           PCR-RFLP            7

  Zhang et al[@b48-copd-11-1367]           2007   People's Republic of China   Asian        Population controls                                        PCR-RFLP            7

  Du et al[@b49-copd-11-1367]              2008   People's Republic of China   Asian        Population controls                                        PCR-RFLP            7

  Gingo et al[@b18-copd-11-1367]           2008   USA                          Non-Asians   Smoking controls                                           PCR-RFLP            7

  Gong et al[@b50-copd-11-1367]            2008   People's Republic of China   Asian        Smoking controls\                                          PCR-RFLP            8
                                                                                            Nonsmoking controls                                                            

  Hsieh et al[@b51-copd-11-1367]           2008   Taiwan                       Asian        Patient controls                                           PCR-RFLP            6

  Li et al[@b52-copd-11-1367]              2008   People's Republic of China   Asian        Population controls                                        PCR-RFLP            5

  Tang et al[@b53-copd-11-1367]            2008   People's Republic of China   Asian        Population controls                                        PCR-RFLP            6

  Zhang and Xiong[@b54-copd-11-1367]       2008   People's Republic of China   Asian        Population controls                                        PCR-RFLP            7

  Stankovic et al[@b55-copd-11-1367]       2009   Serbia                       Non-Asians   Patient controls                                           PCR-RFLP            6

  Trajkov et al[@b13-copd-11-1367]         2009   Macedonia                    Non-Asians   Population controls                                        PCR-SSP             6

  Chen et al[@b56-copd-11-1367]            2010   People's Republic of China   Asian        Smoking controls                                           PCR-RFLP            6

  Yao et al[@b57-copd-11-1367]             2012   People's Republic of China   Asian        Smoking controls\                                          PCR-RFLP            7
                                                                                            Nonsmoking controls                                                            

  Shukla et al[@b58-copd-11-1367]          2012   India                        Non-Asians   Population controls                                        PCR-RFLP            6

  Wang and Ling[@b59-copd-11-1367]         2013   People's Republic of China   Asian        Hospital check-ups                                         PCR-sequencing      7

  Yang et al[@b60-copd-11-1367]            2014   People's Republic of China   Asian        Population controls                                        PCR-RFLP            6

  Ozdogan et al[@b61-copd-11-1367]         2014   Turkey                       Non-Asians   Smoking controls                                           Real-time PCR       6

  Chiang et al[@b62-copd-11-1367]          2014   Taiwan                       Asian        Smoking controls\                                          PCR-RFLP            6
                                                                                            Nonsmoking controls                                                            

  Wu et al[@b63-copd-11-1367]              2014   People's Republic of China   Asian        Hospital check-ups                                         PCR-sequencing      6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Quality score was calculated based on the criteria mentioned in Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603--605.

**Abbreviations:** PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; DBA, dot blot analysis; SSP, sequence-specific primers; ARMS, amplification-refractory mutation system.

###### 

Genotype distribution of the TNF-α −308 G/A polymorphism in case and control

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                    COPD      Control                                                                                     
  ---------------------------------------- --------- --------- ----- ---- ------ ------ ----- --------- ------ ----- ---- ------ -------- ------ -----
  Huang et al[@b16-copd-11-1367]           Yes       27        14    1    42     68     16    Yes       40     2     0    42     0.874    82     2

  Higham et al[@b22-copd-11-1367]          Yes       62        22    2    86     146    26    Mixed\    181\   74\   7\   262\   0.863\   436\   88\
                                                                                              Yes       45     17    1    63     0.670    107    19

  Ishii et al[@b34-copd-11-1367]           Yes       52        1     0    53     105    1     Yes       64     1     0    65     0.950    129    1

  Keatings et al[@b35-copd-11-1367]        Yes       62        38    6    106    162    50    Yes       59     37    3    99     0.324    155    43

  Shi et al[@b36-copd-11-1367]             Unknown   30        23    7    60     83     37    Unknown   32     11    1    44     0.962    75     13

  Kucukaycan et al[@b37-copd-11-1367]      Mixed     113       49    1    163    275    51    Unknown   237    91    7    335    0.612    565    105

  Ferrarotti et al[@b38-copd-11-1367]      Yes       54        9     0    63     117    9     Yes       72     14    0    86     0.411    158    14

  He et al[@b39-copd-11-1367]              Mixed     90        10    1    101    190    12    Mixed     90     6     0    96     0.752    186    6

  Ma et al[@b40-copd-11-1367]              Unknown   72        27    5    104    171    37    Unknown   39     5     0    44     0.689    83     5

  Broekhuizen et al[@b41-copd-11-1367]     Unknown   64        29    6    99     157    41    Unknown   158    64    12   234    0.264    380    88

  Chierakul et al[@b19-copd-11-1367]       Yes       48        9     0    57     105    9     Mixed\    162\   21\   0\   183\   0.509\   345\   21\
                                                                                              Yes       57     10    0    67     0.410    124    10

  Hegab et al[@b42-copd-11-1367]           Yes       91        14    1    106    196    16    Yes       57     14    1    72     0.895    128    16

  Ma et al[@b43-copd-11-1367]              Unknown   35        14    1    50     84     16    Unknown   27     3     0    30     0.773    57     3

  Jiang et al[@b44-copd-11-1367]           Mixed\    90\       10\   1\   101\   190\   12\   Mixed\    90\    6\    0\   96\    0.752\   186\   6\
                                           Yes       60        4     1    65     124    6     Yes       38     3     0    41     0.808    79     3

  Seifart et al[@b24-copd-11-1367]         Yes       64        28    3    95     156    34    Mixed\    171\   67\   4\   242\   0.374\   409\   75\
                                                                                              Yes       74     25    5    104    0.150    173    35

  Brogger et al[@b11-copd-11-1367]         Mixed     154       74    12   240    382    98    Mixed     159    73    12   244    0.343    391    97

  Li et al[@b45-copd-11-1367]              Mixed     56        26    2    84     138    30    Mixed     76     14    0    90     0.424    166    14

  Jiang and Li[@b46-copd-11-1367]          Mixed     55        46    4    105    156    54    Mixed     50     10    0    60     0.481    110    10

  Papatheodorou et al[@b12-copd-11-1367]   Yes       101       14    1    116    216    16    Mixed\    257\   47\   5\   309\   0.051\   561\   57\
                                                                                              Yes       88     18    1    107    0.940    194    20

  Shi et al[@b47-copd-11-1367]             Yes       46        31    11   88     123    53    Yes       69     24    3    96     0.959    162    30

  Zhang et al[@b48-copd-11-1367]           Mixed\    48\       17\   1\   66\    113\   19\   Mixed\    45\    6\    0\   51\    0.655\   96\    6\
                                           Yes       28        8     0    36     64     8     Yes       17     2     0    19     0.808    36     2

  Du et al[@b49-copd-11-1367]              Mixed     90        34    4    128    214    42    Mixed     94     18    0    112    0.355    206    18

  Gingo et al[@b18-copd-11-1367]           Yes       220       67    11   298    507    89    Yes       105    18    2    125    0.250    228    22

  Gong et al[@b50-copd-11-1367]            Yes       55        4     0    59     114    4     Mixed\    76\    8\    0\   84\    0.167\   160\   8\
                                                                                              Yes       36     5     0    41     0.678    77     5

  Hsieh et al[@b51-copd-11-1367]           Mixed\    23\       6\    1\   30\    52\    8\    Mixed\    96\    18\   1\   115\   0.878\   210\   20\
                                           Yes       19        5     1    25     43     7     Yes       35     8     0    43     0.501    78     8

  Li et al[@b52-copd-11-1367]              Mixed     98        46    4    148    242    54    Mixed     124    22    0    146    0.324    270    22

  Tang et al[@b53-copd-11-1367]            No        43        19    0    62     105    19    No        96     12    0    108    0.541    204    12

  Zhang and Xiong[@b54-copd-11-1367]       Unknown   23        18    9    50     64     36    Unknown   33     16    1    50     0.552    82     18

  Stankovic et al[@b55-copd-11-1367]       Mixed     79        17    1    97     175    19    Mixed     71     28    3    102    0.905    170    34

  Trajkov et al[@b13-copd-11-1367]         Mixed     45        14    1    60     104    16    Unknown   231    66    4    301    0.769    528    74

  Chen et al[@b56-copd-11-1367]            Yes       117       28    0    145    262    28    Yes       109    27    3    139    0.398    245    33

  Yao et al[@b57-copd-11-1367]             Mixed     128       48    4    180    304    56    Mixed     302    57    1    360    0.321    661    59

  Shukla et al[@b58-copd-11-1367]          Mixed     178       30    0    208    386    30    Mixed     159    41    4    204    0.483    359    49

  Wang and Ling[@b59-copd-11-1367]         Unknown   58        18    4    80     134    26    Unknown   72     7     1    80     0.116    151    9

  Yang et al[@b60-copd-11-1367]            Mixed     73        25    3    101    171    31    Mixed     71     9     0    80     0.594    151    9

  Ozdogan et al[@b61-copd-11-1367]         Yes       44        16    0    60     104    16    Yes       24     6     0    30     0.543    48     12

  Chiang et al[@b62-copd-11-1367]          Unknown   99        11    0    110    209    11    Mixed     140    4     0    144    0.866    284    4

  Wu et al[@b63-copd-11-1367]              Mixed     109       32    9    150    250    50    Mixed     131    17    2    150    0.113    279    21
  ----------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Mixed smoking status refers to a mixed population of smokers and non-smokers.

**Abbreviation:** HWE, Hardy--Weinberg equilibrium.

###### 

Summary ORs for relationship between the TNF-α −308 polymorphism and COPD risk

  Polymorphism                                            Study        Number of studies   Hypothesis tests    Heterogeneity tests                      
  ------------------------------------------------------- ------------ ------------------- ------------------- --------------------- ------- --- ------ -------
  G vs A                                                  Overall      38                  1.56 (1.29--1.89)   4.55                  0.000   R   70.8   0.000
  GG vs AA (OR1)                                          Overall      38                  1.78 (1.34--2.36)   3.98                  0.000   F   0.0    0.645
  GG vs GA (OR2)                                          Overall      38                  1.51 (1.26--1.81)   4.52                  0.000   R   56.4   0.000
  GA vs AA (OR3)                                          Overall      38                  1.22 (0.90--1.65)   1.24                  0.211   F   0.0    0.988
  Codominant model                                                                                                                                      
   GG vs AA                                               Overall      38                  1.78 (1.34--2.36)   3.98                  0.000   F   0.0    0.645
   GG vs GA                                               Overall      38                  1.51 (1.26--1.81)   4.52                  0.000   R   56.4   0.000
   G vs A                                                 Overall      38                  1.56 (1.29--1.89)   4.55                  0.000   R   70.8   0.000
   GG vs AA                                               Asian        22                  3.25 (2.08--5.08)   5.19                  0.000   F   0.0    0.899
   GG vs GA                                               Asian        22                  2.22 (1.85--2.66)   9.43                  0.000   F   10.3   0.323
   G vs A                                                 Asian        22                  2.40 (1.98--2.90)   11.49                 0.000   F   29.8   0.093
   GG vs AA                                               Non-Asians   16                  1.05 (0.71--1.55)   0.23                  0.818   F   0.0    0.834
   GG vs GA                                               Non-Asians   16                  1.00 (0.86--1.16)   0.01                  0.995   F   0.0    0.504
   G vs A                                                 Non-Asians   16                  0.97 (0.83--1.14)   0.27                  0.785   F   32.5   0.102
   GG vs AA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Overall      15                  1.45 (0.88--2.40)   1.45                  0.146   F   0.0    0.812
   GG vs GA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Overall      15                  1.12 (0.91--1.37)   1.08                  0.279   F   0.0    0.567
   G vs A[a](#tfn5-copd-11-1367){ref-type="table-fn"}     Overall      15                  1.13 (0.95--1.35)   1.39                  0.164   F   34.9   0.089
   GG vs AA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Asian        6                   1.66 (0.75--3.68)   1.26                  0.208   F   24.3   0.252
   GG vs GA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Asian        6                   1.24 (0.85--1.82)   1.10                  0.270   F   24.3   0.433
   G vs A[a](#tfn5-copd-11-1367){ref-type="table-fn"}     Asian        6                   1.26 (0.69--2.30)   0.75                  0.455   R   52.2   0.063
   GG vs AA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Non-Asians   9                   1.32 (0.69--2.53)   0.85                  0.396   F   0.0    0.961
   GG vs GA[a](#tfn5-copd-11-1367){ref-type="table-fn"}   Non-Asians   9                   1.07 (0.84--1.37)   0.59                  0.558   F   0.0    0.511
   G vs A[a](#tfn5-copd-11-1367){ref-type="table-fn"}     Non-Asians   9                   1.06 (0.86--1.30)   0.51                  0.608   F   15.8   0.301

**Notes:**

Only cases and controls with smoking history. Results are in response to a chi-square-based Cochran *Q*-test to test for heterogeneity.

**Abbreviations:** OR, odds ratio; CI, confidence interval; R, random model; F, fixed model.
